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Scaffold
TerminationNF-κB is an important regulator of immunity and inﬂammation, and its activation pathway has been studied ex-
tensively. The mechanisms that downregulate the activity of NF-κB have also received a lot of attention, partic-
ularly since its activity needs to be terminated to prevent chronic inﬂammation and subsequent tissue
damage. The COMMD family has been identiﬁed as a new group of proteins involved in NF-κB termination. All
ten COMMD members share the structurally conserved carboxy-terminal motif, the COMM domain, and are
ubiquitously expressed. They seem to play distinct and non-redundant roles in various physiological processes,
including NF-κB signaling. In this review, we describe the mechanisms and proteins involved in the termination
of canonical NF-κB signaling, with a speciﬁc focus on the role of the COMMD family in the down-modulation of
NF-κB.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The nuclear factor-κB (NF-κB) family of transcription factors regu-
lates the expression of a wide array of genes involved in various physi-
ological processes, including immunity and inﬂammation. The central
role of NF-κB in these processes is to recruit and activate various im-
mune cells by inducing transcription of proinﬂammatory mediators
like cytokines, chemokines and adhesion molecules. This process aims
to protect the host efﬁciently against different kinds of pathogens and
injuries. However, it is essential that in the end NF-κB activity is down-
regulated in order to prevent chronic inﬂammation. Uncontrolled in-
ﬂammation can be accompanied by tissue damage (reviewed in [1])
and can have a critical role in the development and pathogenesis of nu-
merous diseases, like inﬂammatory bowel disease, atherosclerosis, dia-
betes and cancer [2–7]. Therefore, NF-κB activity during inﬂammatorynductance regulator; COMMD,
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ights reserved.responses needs to be tightly spatiotemporally regulated. This review
discusses several pathways down-modulating NF-κB activity, and pays
special attention to the role of the COMMD family of proteins in NF-κB
signaling.
The NF-κB family comprises ﬁvemembers: RELA (p65), RELB, c-REL,
p50/p105 (NF-κB1), and p52/p100 (NF-κB2), which all share the
amino-terminal REL homology domain (RHD). The RHD is essential for
various events, such as NF-κB dimerization, interaction with inhibitors
of κΒ (IκB), nuclear translocation and binding to DNA. RELA, c-REL and
RELB proteins also have a transcriptional activation domain (TAD) at
the carboxy-terminus, which is important for the transcription of NF-
κB target genes. The TAD is absent in the NF-κB subunits p50 and p52,
therefore they can function as transcriptional repressors (reviewed in
[8]). Whether NF-κB acts as a transcriptional activator or repressor
depends on the dimer combination formed by the NF-κB members.
NF-κB dimers which contain at least one member with a TAD activate
transcription through displacement of repressors, such as the histone
deacetylases 1 and 2 (HDAC1 and HDAC2), and recruitment of co-
activators, i.e. HDAC3 [9,10] and the histone acetylases, CBP/p300
[11–13]. In contrast, p50 and p52 homodimers or p50/p52 hetero-
dimers, which both bind to κB-sites, have been shown to have a tran-
scriptionally repressive function. This function is manifested by
recruiting transcriptional repressors, such as HDAC1 [14,15].
Theway that NF-κB is activated can be divided into various signaling
pathways, including the canonical (or classical) and the non-canonical
(or alternative) pathway.Which of the signaling events occurs depends
on the type of stimuli. The canonical pathway is activated by a wide
range of stimuli, such as the proinﬂammatory cytokines, tumor necrosis
factor (TNF), interleukin-1 (IL-1) and the bacterial endotoxin, lipopoly-
saccharide (LPS). These stimuli activate the NF-κB dimer RELA/p50
through the receptors: TNF receptor (TNFR), interleukin 1 receptor
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canonical pathway can be activated by lymphotoxin beta, B cell activat-
ing factor, or CD40 ligand. This activation induces the processing of p100
that results in RELB/p52 mediated transcription. Since we will focus
mainly on the regulation of the canonical pathway here, we recommend
readers to other reviews for further information on the non-canonical
and other pathways in NF-κB activation (for example [16–18]).
In the canonical NF-κB pathway, the NF-κB dimer RELA/p50 is kept
in the cytosol in an inactive state by the IκB proteins. These proteins re-
tain RELA/p50 dimers in the cytosol by masking their nuclear localiza-
tion signal (NLS) (Fig. 1). This prevents translocation of RELA/p50 to
the nucleus. However, it has been indicated that IκB proteins, namely
IκBα and IκBε, also have the ability to shuttle NF-κB from the nucleus
back to the cytoplasm. This is regulated by the nuclear export signal
(NES) within these proteins, which is absent in the other IκB proteins.
Upon phosphorylation of the IκB proteins by the IκB kinase (IKK) com-
plex, IκB proteins are ubiquitinated and subsequently degraded by theRELA
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IκBα. Transcribed and newly synthesized A20 inhibits NF-κB by interferingwith the IKK compl
results in dampened IKK activity. PIAS1, PIAS4, COMMD1, and PDLIM2 act on NF-κB activity in
ubiquitination and proteasomal degradation.proteasomes (Fig. 1). This results in nuclear translocation of RELA/p50.
Dimeric combinations of RELA subunit (NF-κB) bind to the DNA regions
upstream of speciﬁc genes to alter their transcription.
The IKK complex consists of two catalytic subunitswith kinase activ-
ity (IKKα/IKK1 and IKKβ/IKK2) and a regulatory subunit (IKKγ, also
known as NEMO) [19]. IKK activation is mediated by different protein
complexes downstream of various receptors that are responsible for
the initial NF-κB activation (reviewed in [20]). This pathway has been
studied extensively since NF-κB was ﬁrst identiﬁed in 1986 [21]. How-
ever, there is still relatively little known about themechanisms that ter-
minate its transcriptional activity or the signaling events that are
essential to resolve inﬂammation and prevent autoimmune disease.
2. Down-modulators of NF-κB
To this day, only a few proteins have been shown to negatively reg-
ulate NF-κB signaling [22,23]. Among them are the IκB proteins (IκBα,p50
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rough various receptors lead to a number of signaling events and result in activation of the
dedby the proteasome. COMMD8enhances the degradation of IκBα and hereby stimulates
nucleus to activate the transcription of several genes, including its own inhibitors, A20 and
ex, whereas IκBα sequesters NF-κB in the cytosol. CYLD deubiquitinates NEMO, which also
the nucleus, either interfering with the binding of NF-κB to the DNA or leading to NF-κB
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IκBε is induced as a negative feedback loop mechanism. Although the
expression of IκBε is markedly delayed compared to IκBα, both newly
synthesized IκB proteins sequester NF-κB in the cytosol in order to ham-
per the activity of NF-κB [24] (Fig. 1). On the contrary, it has been shown
that hypophosphorylated IκBβ can form a DNA-bound protein complex
with RELA, which leads to prolonged expression of NF-κB target genes
[25]. Thus IκBβ can regulate NF-κB either negatively or positively. In ad-
dition to the IκB proteins, the protein A20/TNFAIP3 similarly serves as a
negative feedback loop,with its expression also driven byNF-κB (Fig. 1).
The deubiquitinating (DUB) enzymatic activity of A20 is responsible for
removal of the K63-linked polyubiquitin chains from the receptor-
interacting protein 1 (RIP1). At the same time, the E3 ubiquitin ligase
domain of A20 promotes K48-ubiquitinmediated RIP1 protein degrada-
tion [26]. In addition to RIP1, A20 also deubiquitinates other IKK regula-
tors, such as NEMO and TRAF6. This event eventually results in
downregulation of the canonical NF-κB signaling cascades. The impor-
tance of this negative feedback loop mechanism is illustrated in several
murine models. Haploinsufﬁciency for A20 in apolipoprotein E-
deﬁcient mice leads to increased atherosclerotic lesion size and condi-
tional depletion of A20 in certain murine cell types, such as B-cells,
dendritic cells (DCs), intestinal epithelial cells or macrophages and
granulocytes, leads to hypersensitivity to various inﬂammatory dis-
eases, such as colitis and nephritis [27,28]. Furthermore, complete deﬁ-
ciency of A20 results in early death due to uncontrolled inﬂammation.
Of note, human single nucleotide polymorphisms (SNPs) within the
A20 gene have been associated with susceptibility to several diseases
like rheumatoid arthritis, psoriasis, celiac disease, Crohn's disease, sys-
temic sclerosis, and type 1 diabetes. Moreover, A20 insufﬁciency has
been shown to play an important role in human B cell lymphoma [27].
Another protein playing a role in dampening the activity of NF-κB is
the DUB protease, cylindromatosis (CYLD) [29–31]. CYLD deubiqui-
tinates NEMO and several other upstream proteins like RIP1, TAK1,
TRAF2, 6, and 7 [29]. The K63-linked ubiquitin chains removed by
CYLD are essential for down-modulation of IKK activity (Fig. 1). Cyld-
deﬁcient mice are prone to inﬂammation and tumor formation in vari-
ous experimental mouse models [32,33]. In humans, mutations in
CYLD are associated with the development of cylindromas (tumors of
the skin) [34–36]. In contrast, Cyld-deﬁcient mice do not develop skin
tumors spontaneously, but are sensitive to chemically induced skin tu-
mors. Furthermore, reduced expression of CYLD has been observed in
colon and liver cancers in humans [37]. Together, these experimental
murine models and human genetic studies underline the importance
of NF-κB down-modulation in preventing uncontrolled inﬂammation
and the development of diseases associated with inﬂammation.
All the events described above control NF-κB activity by acting up-
stream of NF-κB. However, little is known about the mechanisms
through which NF-κB activity is terminated within the nucleus. In addi-
tion to IκBα, which relocates active RELA from nucleus back to the cyto-
sol for proteasomal degradation [38], other proteins that directly inhibit
NF-κB at the DNA level have been identiﬁed. These include PDZ and LIM
domain containing protein 2 (PDLIM2), protein inhibitor of activated
STAT (PIAS), and COMMD1 (Fig. 1). PDLIM2 is an ubiquitin E3 ligase
[39], which directs RELA from the nucleus into subnuclear domains,
also known as promyelocytic leukemia protein (PML) nuclear bodies
[40]. Upon polyubiquitination by PDLIM2, RELA is degraded by the
proteasomes within the PML nuclear bodies. Pdlim2-deﬁcient mice are
more sensitive to LPS-induced sepsis, illustrating the importance of
PDLIM2 in restraining inﬂammation [39].
PIAS1 interferes with the binding of NF-κB to the κB-sites of NF-κB
target genes. In a similar fashion to Pdlim2 null mice, loss of Pias1 in
mice results in hypersensitivity to endotoxic shock [41]. The latter has
also been observed in Pias4-deﬁcient mice, indicating that Pias1 and
Pias4 are not redundant in this speciﬁc pathway [42]. In addition to
the previously discussed proteins, COMMD1, a member of the
COMMD family of proteins, has been identiﬁed as playing a role interminating NF-κB at the level of DNA. Similar to PIAS1 and PIAS4,
COMMD1 inhibits the expression of a speciﬁc subset of NF-κB target
genes [43]. The mechanism by which COMMD1 down-modulates NF-
κB will be described in the following paragraphs.
3. The COMMD protein family
3.1. COMMDs — a family of NF-κB regulators
Using a positional cloning strategy, COMMD1 was ﬁrst identiﬁed to
be mutated in Bedlington terriers suffering from copper toxicosis [44].
Copper toxicosis is characterized by copper accumulation in the liver
until reaching toxic levels resulting in pathological changes (the role
of COMMD1 in copper homeostasis is discussed in Section 3.5 of this
manuscript). Soon after this discovery, E. Burstein and colleagues dem-
onstrated that COMMD1 belongs to a new family of proteins, called the
copper metabolism gene MURR1 domain-containing (COMMD) family
[45]. This family consists of tenmembers and is highly conserved in var-
ious multicellular organisms and in some protozoa. The COMMD
proteins have a structurally conserved carboxyl-terminal coppermetab-
olism geneMURR1 (COMM) domain [45] (Fig. 2). This domain serves as
a platform for COMMD interactions with each other and with their
interacting partners. The amino-terminal region is unique in each
COMMD protein, but is almost absent in COMMD6, as COMMD6 prima-
rily encodes the COMM domain (Fig. 2). All COMMD proteins, including
COMMD1, were shown to interact with COMMD1 [45,46]. The COMMD
proteins are ubiquitously expressed, but the level of mRNA expression
of each COMMD varies within and between different tissues [44,45].
As an example, oligonucleotide microarray data demonstrated that
COMMD1 is highly expressed in the testis and heart, but much less so
in skin [45]. Nevertheless, there seems to be no direct correlation be-
tween mRNA and protein expression, since the highest protein levels
of COMMD1 in mice are seen in kidney, colon, spleen and liver [47]. Of
note, no catalytic activity has been assigned to the COMMD proteins.
Although in recent years more insight into the function of COMMD1
has been obtained, very little is known about the function of the other
COMMD proteins. Nonetheless, according to Burstein et al. [45], all
COMMD proteins are able to interact with different subunits of NF-κB.
Additionally, based on a luciferase κB-reporter assay, each COMMD
member, when overexpressed, inhibits TNF-induced NF-κB activity
[45,46]. Of note, only COMMD1 is able to interact with all ﬁve subunits
of NF-κB, whereas the other COMMDs show a selective interaction pat-
tern with NF-κB subunits [45]. Moreover, only an association between
COMMD1 and IκBα has been identiﬁed so far [46,48]. It is therefore like-
ly that the mechanism by which each COMMD protein regulates NF-κB
is distinct.
3.2. COMMD1 — a hub in NF-κB termination
Despite the fact that all ten COMMD proteins interact with NF-κB, so
far a detailed mechanism has only been described for COMMD1: it in-
hibits NF-κB by promoting the ubiquitination and subsequent protea-
somal degradation of RELA bound to chromatin [43,45] (Fig. 3).
Depletion of COMMD1 results in prolonged nuclear RELA levels upon
NF-κB activation, which coincides with increased and sustained ex-
pression of a speciﬁc group of NF-κB target genes. COMMD1 also
downregulates the levels of RELB, p105 and p100. As shown initially
for COMMD1 knockdown, the level of polyubiquitinated RELA was
also reduced in cells insufﬁcient for either COMMD6, 9 or 10 [43].
These data indicate that other COMMD proteins also mediate NF-κB ac-
tivity by regulating the turnover of RELA, butmore studies are needed to
conﬁrm this.
COMMD1 interacts with amultimeric E3 ubiquitin ligase complex of
proteins, the ECSSOCS1. This complex contains Elongins B and C, Cullin 2
and SOCS1 (Fig. 3).Within the ECSSOCS1 complex, COMMD1acts as a hub
to facilitate the interaction between RELA and SOCS1, which results in
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Fig. 2. COMMD family of proteins. The COMMD family consists of 10 members. They all share a structurally conserved C-terminal motif, namely the COMM domain. On the other hand,
their N-terminal region shows no homology between the different COMMDproteins, but is highly conserved across species. COMMD1 is designated as the prototype of the family.Within
the COMM domain, COMMD1 has two NES sequences (indicated by red boxes). Putative NESs in other COMMDs are indicated by HHHH and are based on the consensus NES sequence of
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COMMD1 occupies the promoter sites of a speciﬁc subset of genes.
This indicates that COMMD1 may also reduce the expression of NF-κB
target genes by this additional mechanism. The fact that COMMD1
does not contain a DNA-binding motif suggests that it is in a complex
with other proteins that occupy these speciﬁc promoter sites. However,
the composition of this possible protein complex still has to be identiﬁed.
The importance of Ser468-phosphorylated RELA in NF-κB termina-
tion was conﬁrmed by Mao et al. [52]. They showed that this speciﬁc
post-translational event is important for the interaction of RELA with
the histone acetyltransferase GCN5. In complex with COMMD1, GCN5
facilitates the ubiquitin-dependent proteasomal degradation of RELA.
Although Mao et al. showed that IKKα and IKKβ are important for this
phosphorylation-dependent regulation, Geng et al. indicated that it is
particularly IKKε that regulates the phospho-S468 mediated RELA deg-
radation [49,52]. Of note, an interaction between COMMD10 and GCN5
has also been observed, but the biological relevance of this association is
not yet understood.
3.3. Functional regulation of COMMD1
Although COMMD1 is predominantly localized in the cytosol, low
levels have also been observed in the nucleus [53–58]. Since it is a rela-
tively small protein (21 kDa) and does not contain a nuclear localization
signal (NLS), it is likely that COMMD1 enters the nucleus by diffusion
through the nuclear pores. However, its transport from the nucleus
back to the cytosol seems to be tightly regulated. COMMD1 has two nu-
clear export signals (NESs) (Fig. 2) [55], which are recognized by CRM1
(Exportin 1), a nuclear export receptor present predominantly at the
nuclear membrane (Fig. 3). Mutation of the NES or CRM1 inhibition
leads to an increase in nuclear COMMD1. COMMD1 NES mutants aug-
ment the inhibitory function of COMMD1 on NF-κB. A similar role for
NES to regulate the nuclear levels of COMMD1 and hereby its inhibitory
effect during hypoxia was demonstrated [55]. NES mutations in
COMMD1 reduce hypoxia-driven export of nuclear COMMD1 and coin-
cide with greater inhibition of COMMD1 on hypoxia-inducible factor-1
(HIF-1) activity [55]. The hydrophobic residues forming the NES (NES
consensus sequence of HX2–3HX2–3HX1–2H) are conserved among the
COMMD proteins (Fig. 2) [55], but the role of these residues in nuclear
localization of the COMMD proteins needs to be investigated.
Cytosolic COMMD1 can be polyubiquitinated by either X-linked in-
hibitor of apoptosis (XIAP) [53] or redox sensor protein HSCARG [58].
Both XIAP and HSCARG add K48- polyubiquitin chains to COMMD1,
which direct COMMD1 for proteasomal degradation (Fig. 3). Thismech-
anism likely controls COMMD1 levels and thereby its function onNF-κB.
However, at themoment, only a role for XIAP in coppermetabolism and
COMMD1 regulation has been proposed [53,61]. Intracellular copper
enhances the degradation of XIAP and sensitizes cells to apoptosis
[61]. Since COMMD1was initially identiﬁed as a novel modulator of he-
patic copper homeostasis, these results might accentuate the link be-
tween XIAP and COMMD1 in this speciﬁc pathway [44,61–64].
In addition to K48-linked ubiquitinmodiﬁcation, the tumor suppres-
sor ARF promotes the K63-mediated polyubiquitnation of COMMD1
[65]. K63-polyubiquitination of COMMD1 augments its protein stability
and enhances its nuclear levels (Fig. 3). The association between ARF
and COMMD1 seems to depend on particular physiological conditions.
Upon DNA damage, COMMD1 interacts and colocalizes with ARF.
Whether thismechanism is involved in COMMD1-mediatedNF-κB inhi-
bition or in other pathways, such as DNA-damage signaling [66], needs
to be evaluated.
Apart from the ubiquitination, no other protein modiﬁcations of
COMMD1 have been reported to date. However, several physiological
conditions have been described that affect COMMD1 levels. For ins-
tance, chronic copper overload reduces the mRNA and protein levels
of COMMD1 in the hepatocellular carcinoma cell line HepG2 [67]. In
contrast, increased COMMD1 expression was seen in cells subjected toaspirin [68]. This increase is associated with enhanced RELA-COMMD1
interaction and nucleolar distribution of RELA. Downregulation of
COMMD1 desensitizes cells for aspirin-induced apoptosis, possibly
through increased expression of NF-κB-mediated anti-apoptotic genes,
although these particular changes were not examined in the study of
Thoms et al. [68].
Interestingly, the stress-induced small heat-shock chaperone secre-
tory clusterin (sCLU) also mediates the protein levels of COMMD1 [54]
(Fig. 3). sCLU is negatively correlated with COMMD1 protein levels,
but positively correlated with the expression of various NF-κB-target
genes linked with cellular survival. Increased sCLU expression is associ-
ated with the survival of cancer cells treated with a wide range of anti-
cancer treatments, such as chemotherapy or radiation therapy. In line
with these results, decreased expression of COMMD1 is observed in sev-
eral cancers. Lower COMMD1 expression has been correlated with in-
creased invasion of tumor cells and a reduced survival rate of patients
with endometrial cancer [69]. However, whether the expression of
sCLU and COMMD1 is inversely correlated within various cancers, or
whether this correlation is associated with tumor behavior, needs to
be investigated.
Altogether, depending on the physiological conditions, COMMD1
function can be modulated through various mechanisms, including
regulation of its protein expression, mRNA expression, and nucleo-
cytoplasmic transport. The biological consequences of these alterations
on COMMD1's function in NF-κB signaling or on other COMMD1-
mediated processes require further study.
3.4. COMMD proteins as binding partners of Cullins
As described previously, all members of the COMMD family have the
ability to inhibit NF-κB activity. However, except for COMMD1, the exact
mechanisms are still unknown. In addition to COMMD1 [43,45,48], all
the other COMMD proteins physically associate with different Cullins
[56]. Cullin proteins act as core scaffold proteins and together with
RING box protein (Rbx1 or Rbx2) form the Cullin-RING-ligases (CRLs).
CRLs are the largest family of ubiquitin ligases, and they mediate
ubiquitination of a wide range of proteins in various physiological pro-
cesses [70]. Identiﬁcation of the ability of COMMD proteins to interact
with and regulate different CRLs intensiﬁes the complexity and, pre-
sumably, also the speciﬁcity of this regulatorymechanism. It is therefore
likely that, depending on the physiological conditions, each COMMD
protein acts as a hub to control several processes, including NF-κB
signaling.
Indeed, as recently indicated, COMMD8 is in complex with the
coiled-coil domain-containing protein (CCDC22) and Cullin1 and medi-
ates the protein degradation of IκΒα. Depletion of COMMD8 impairs
IκBα degradation and, consequently, reduces NF-κB transcriptional ac-
tivity [71]. AlthoughCCDC22-COMMD1andCCDC22-COMMD10protein
complexes were also observed, loss of either COMMD1 or COMMD10
does not affect IκBα degradation. This suggests that COMMD8 is essen-
tial for the activation of NF-κB,whereas COMMD1 is important for NF-κB
termination.
Overall, COMMD proteins interact with speciﬁc Cullin-associated
complexes and might serve as a hub to regulate the speciﬁcity of CRLs.
3.5. COMMD1, a multifunctional protein
In addition to its role in NF-κB signaling, COMMD1 is also associated
with other physiological processes. As mentioned in Section 3.1 of this
manuscript, COMMD1was identiﬁed as a proteinmediating copperme-
tabolism in the liver [44,64]. Its role in maintaining hepatic copper ho-
meostasis by promoting copper export to the bile was validated in a
hepatic Commd1-deﬁcientmousemodel [63]. COMMD1 facilitates cop-
per excretion from the liver into the bile, possibly through the copper
transporting protein ATP7B [44,64,72,73]. Interestingly, COMMD1 deﬁ-
ciency in various cell lines also affects the transporting capacity of
2320 P. Bartuzi et al. / Biochimica et Biophysica Acta 1832 (2013) 2315–2321ATP7A, a copper transporting protein that is highly homologous to
ATP7B [73]. However, to date, no polymorphisms or mutations in
COMMD1 have been found to be associated with human copper over-
load diseases.
COMMD1 also plays a role in processes like sodium uptake (through
regulation of epithelium sodium channel, ENaC, cell surface expression)
[74], HIF-1 signaling [59,60,69], cystic ﬁbrosis (through interactionwith
cystic ﬁbrosis transmembrane conductance regulator, CFTR) [57] and
maturation of superoxide dismutase 1 (SOD1) [75]. The commonmech-
anism of COMMD1 action inmost of these processes seems to be its role
in regulating the protein stability and/or in ubiquitination of its targets.
It has also been shown that COMMD1mediates the trafﬁcking of its tar-
gets within the cell [57,76]. Whether ubiquitination is directly involved
in all these process is still uncertain.
The pleiotropic function of COMMD1 is represented by the lethal
phenotype of the Commd1 knockout mouse. In contrast to COMMD1
deﬁciency in dogs, loss of Commd1 in mice results in early embryonic
lethality [59]. These mice die between embryonic stages E9.5 and
E10.5. The importance of Commd1 in mouse embryogenesis was con-
ﬁrmed by reintroducing human COMMD1 into the Commd1 knockout
mice (B. van de Sluis, unpublished data). Mice deﬁcient in endogenous
COMMD1, but expressing the human COMMD1 variant are born with
the expected Mendelian ratio and do not show any overt phenotype.
The exact reason for the discrepancy between dogs and mice is un-
known, but it is possible that during embryogenesis in dogs other
COMMD proteins can take over the function of COMMD1. Evidence for
the lack of non-redundancy of the COMMD proteins in mice is illustrat-
ed by the fact that genetic deletion of either COMMD1, 6, 9 or 10 results
in embryonic lethality ([59]; E. Burstein and B. van de Sluis, personal
communication). Furthermore, the stage of prenatal death and themor-
phology of the affected embryos differ between the COMMD-deﬁcient
embryos, indicating that each COMMD protein regulates a speciﬁc
vital pathway during embryogenesis.
4. Concluding remarks
Since the discovery of NF-κB, much has been learnt about how it is
regulated. In recent years, the termination of NF-κB to down-modulate
its response has also attracted a lot of attention. As shown by various ex-
perimental mousemodels, downregulation of NF-κB plays a crucial role
in neutralizing inﬂammation. In this review we have brieﬂy considered
several new regulators of NF-κB, paying special attention to the COMMD
family of proteins. Currently, most of what we know about the role of
this family in NF-κB signaling comes from in vitro studies. These have fo-
cusedmainly on themechanisms bywhich COMMD1, thought to be the
prototype of the COMMD family, terminates NF-κB signaling. Yet recent
data on COMMD8 in NF-κB modulation suggest that each COMMD pro-
tein regulates NF-κB activity in a different manner. This is supported by
the different patterns of each COMMD protein–protein network. There
is still much to be learned about how this family acts on NF-κB signaling
and about its possible roles in many other pathways.
Lack of any catalytic activity suggests that COMMDs act as scaffold
proteins to facilitate the assembling of crucial molecular components
involved in a number of biological processes, including copper homeo-
stasis, NF-κB and HIF-1 signaling. Nevertheless, the biological relevance
of COMMD1 and the other COMMDproteins in NF-κB-mediated inﬂam-
mation needs to be investigated. It would be of interest to ﬁnd any poly-
morphisms or mutations within the COMMD genes associated with the
susceptibility to inﬂammatory diseases, such as inﬂammatory bowel
disease (IBD). Furthermore, to advance thisﬁeld,we andour collaborator
(E. Burstein) are using genetically engineered mice to elucidate the role
of various COMMD proteins (i.e. COMMD1, COMMD6 and COMMD9)
in the pathogenesis of different diseases associated with inﬂammation.
We are conﬁdent that these mouse models will soon provide new in-
sights into the regulatory mechanisms of inﬂammation and will help us
to understand the functions of this protein family.Acknowledgements
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